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Abstract
Background: To evaluate the expression and test the clinical significance of the epithelial cellular
adhesion molecule (Ep-CAM) in esophageal squamous cell carcinoma (SCC) to check the suitability
of esophageal SCC patients for Ep-CAM directed targeted therapies.
Methods:  The Ep-CAM expression was immunohistochemically investigated in 70 primary
esophageal SCCs using the monoclonal antibody Ber-EP4. For the interpretation of the staining
results, we used a standardized scoring system ranging from 0 to 3+. The survival analysis was
calculated from 53 patients without distant metastasis, with R0 resection and at least 2 months of
clinical follow-up.
Results: Ep-CAM neo-expression was observed in 79% of the tumors with three expression levels,
1+ (26%), 2+ (11%) and 3+ (41%). Heterogeneous expression was observed at all expression levels.
Interestingly, tumors with 3+ Ep-CAM expression conferred a significantly decreased median
relapse-free survival period (log rank, p = 0.0001) and median overall survival (log rank, p = 0.0003).
Multivariate survival analysis disclosed Ep-CAM 3+ expression as independent prognostic factor.
Conclusion: Our results suggest Ep-CAM as an attractive molecule for targeted therapy in
esophageal SCC. Considering the discontenting results of the current adjuvant concepts for
esophageal SCC patients, Ep-CAM might provide a promising target for an adjuvant
immunotherapeutic intervention.
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Background
Advances in surgical techniques over the last decade
improved the outcome of patients with squamous cell car-
cinomas (SCC) of the esophagus significantly. However,
in comparison to other gastrointestinal malignancies,
esophageal SCC belongs to the more aggressive tumors
with 5-year survival rates averaging below 30 per cent
[1,2]. From the survival data of patients receiving surgery
with curative intention it is obvious, that at the time of ini-
tial diagnosis in most patients unperceived tumor cell
spread has occurred. The results of current multimodal
adjuvant and neoadjuvant strategies for esophageal SCC
to eliminate the minimal residual tumorload are still
unsatisfactory and due to their unspecificity afflicted with
significant side effects [3-5]. Therefore new adjuvant ther-
apeutic concepts are urgently needed to eradicate effec-
tively the minimal residual disease and to improve the
post-operative prognosis of esophageal SCC patients.
A promising basis for new systemic anti-cancer therapy
represents the epithelial cellular adhesion molecule Ep-
CAM, encoded by the 9-exon gene TACSTD1 [6,7] (Ep-
CAM, EGP 40, GA733-2, 17-1A) that was recently re-
mapped to chromosome 2p21 [8]. EpCAM is a 40 kD type
I transmembrane glycoprotein with two epidermal
growth factor like repeats in the external domain and a
short intracellular domain consisting of two α-actin bind-
ing sites for actin cytoskeleton linkage and functions as an
intercellular adhesion molecule modulating cadherin-
mediated adhesions and thereby adhesion strength [9-
12]. The physiologic expression of Ep-CAM in adult
human tissues is strictly restricted to the basolateral cell
membrane of glandular, pseudo-stratified and transi-
tional epithelia, whereas normal squamous stratified epi-
thelia are Ep-CAM negative [13]. Interestingly, de novo
expression of Ep-CAM occurs during squamous cell car-
cinogenesis of the oral cavity and of the lung[14]. The
expression level increases during the progression from
mild dysplasia to carcinoma [14]. Although the biological
role of Ep-CAM in healthy tissues and in cancer is not
understood conclusively, its overexpression is observed in
several cancer types and has been associated with poor
prognosis in breast cancer [15,16] and gallbladder cancer
[17]. Of much interest, from the clinical point of view, is
the possibility to use Ep-CAM as a target for immuno-
therapy [18-21]. So far, very few data are available regard-
ing Ep-CAM expression in esophageal cancer. Here we
investigated the expression and prognostic impact of Ep-
CAM in esophageal SCC to test the potential value of this
molecule for antibody based adjuvant therapy in this
aggressive cancer.
Methods
The ethics committee of the chamber of physicians of
Hamburg approved this study. Informed consent was
obtained from all patients before inclusion into the study.
Tumor samples were collected from 70 patients with
resectable esophageal carcinoma who had undergone rad-
ical en bloc esophagectomy at the University Hospital
Hamburg Eppendorf, Germany. Tumor stage and grade
were classified by the routine histopathologic assessment
according to the UICC (Union Internationale Contre le
Cancer) Classification for Malignant Tumors [22,23] from
pathologists unaware of the immunohistochemical find-
ings. The survival analysis was calculated from 53 patients
with R0 resection, where at least two months of prospec-
tively evaluated clinical follow-up was available. Seven-
teen patients were excluded from the survival analysis
because of metastatic disease (n = 5), perioperative death
(n = 5), non-tumor free resection margins (n = 5) and lost
for follow-up (n = 2). The clinico-pathologic data are pre-
sented in Table 1 (all patients) and in Table 2 (the 53
patients included in the survival analysis).
Tissue preparation and immunohistochemistry
The tumor tissue was snap-frozen in liquid nitrogen
immediately after removal and stored at -80°C until use.
The Ep-CAM antigen was detected with the monoclonal
antibody Ber-EP4 (IgG1, Dako, Hamburg, Germany),
which can be used on snap frozen material as described
previously[24]. Briefly, 5 μm cryostat sections were cut
from each tumor and were transferred onto glass slides
pretreated with 3-triethoxysilyl-propylamin (Merck,
Darmstadt, Germany). One section was stained with con-
ventional hematoxylin an eosin (H & E) staining and the
following section was stained using the alkaline phos-
phatase-antialkaline phosphatase (APAAP) tech-
nique[24]. Sections of normal colonic mucosa and MCF-
7 cells served as positive staining controls, and isotype-
matched, irrelevant murine monoclonal antibodies
served as negative controls (MOPC 21 for IgG1; Sigma,
Deisenhofen, Germany). For the evaluation of the Ep-
CAM staining we used standardized criteria to evaluate
membranous staining specified by Dako for interpreta-
tion of the HercepTest for p185HER2 expression. The Dako
scoring system has a scale from 0 - 3+: 0, no staining or
10% or less of the tumor cells show any level of positive
staining; 1+, a faint membrane staining is detected in
more than 10% of the tumor cells or the cells are only
stained in part of their membrane; 2+, weak to moderate
staining of the entire membrane is observed in more than
10% of the tumor cells; 3+, strong staining of the entire
membrane in more than 10% of the tumor cells. Hetero-
geneous staining was defined as different staining inten-
sity in more than 25% of Ep-CAM-positive tumor cells.
The inter-observer reproducibility in our study was 93%.
The slides with discrepant assessments were reevaluated,
and a consensus was reached in all cases.BMC Cancer 2006, 6:165 http://www.biomedcentral.com/1471-2407/6/165
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Statistical analysis
To test the correlation between the clinico-pathological
data and the level of Ep-CAM expression we used the
Fisher's exact test and whenever appropriate the χ2-test.
All of the variables were dichotomised. For analysis of fol-
low-up data, life table curves were calculated using the
Kaplan-Meier method, and survival distributions were
compared using the log-rank test. The primary end points
were disease-specific survival or relapse-free survival, as
measured from the date of surgery to the time of the last
follow-up or cancer-related death or tumor relapse,
respectively. Data of patients who were still alive and
without evidence of tumor relapse at the end of the study
were censored. For multivariate analysis, a parametric sur-
vival regression model based on a Weibull distribution
was applied. Model selection was carried out using the
Bayesian Information Criterion (BIC) [25,26]. This infor-
mation criterion was adopted to search for a parsimoni-
ous model that fit the data [27]. The lower the BIC the
better the model explains the data. A search in the model
space was done with a stepwise algorithm. The range of
the models examined in the stepwise search was from the
simplest model with a constant term, to the most complex
model with all covariates included. The investigated dis-
tributions were loglogistic, lognormal, logistic, exponen-
tial, Gaussian and Weibull. Both, the exponential and the
Weibull distributions fitted the data best. Because the
exponential distribution is a particular case of the Weibull
when the scale parameter equals one, we decided to use
the Weibull distribution. Statistical computations were
Table 2: Patient and tumor characteristics of the 53 patients with clinical follow-up data (The numbers in parenthesis are 
percentages).*
Ep-CAM expression
Variable Patients 0 1+ 2+ 3+
Patients 10 15 7 21
Male 39 (74) 8 (80) 10 (67) 4 (57) 17 (81)
Female 14 (26) 2 (20) 5 (33) 3 (43) 4 (19)
Primary Tumor
pT1 15 (28) 4 (40) 3 (20) 3 (42) 5 (24)
pT2 8 (15) 1 (10) 2 (13) 2 (29) 3 (14)
pT3 30 (57) 5 (50) 10 (67) 2 (29) 13 (62)
Lymph node status
pN0 27 (51) 4 (40) 9 (60) 5 (71) 9 (43)
pN1 26 (49) 6 (60) 6 (40) 2 (29) 12 (57)
Tumor grade
G2 38 (72) 7 (70) 11 (73) 5 (71) 15 (71)
G3 15 (28) 3 (30) 4 (27) 2 (29) 6 (29)
*No statistical significant correlations between Ep-CAM expression and histopathological parameters were observed.
Table 1: Patient and tumor characteristics (The numbers in parenthesis are percentages).*
Ep-CAM expression
Variable Patients 0 1+ 2+ 3+
Patients 15 18 8 29
Male 50 (71) 10 (67) 12 (67) 5 (38) 23 (79)
Female 20 (29) 5 (33) 6 (33) 3 (62) 6 (21)
Primary Tumor
pT1 15 (21) 4 (27) 3 (17) 3 (38) 5 (17)
pT2 11 (16) 3 (20) 2 (11) 2 (24) 4 (14)
pT3 42 (60) 8 (53) 11 (61) 3 (38) 20 (69)
pT4 2 (3) 0 (0) 2 (11) 0 (0) 0 (0)
Lymph node status
pN0 33 (47) 7 (47) 9 (50) 6 (75) 11 (38)
pN1 37 (53) 8 (53) 9 (50) 2 (25) 18 (62)
Tumor grade
G2 47 (67) 10 (67) 12 (67) 6 (75) 19 (66)
G3 23 (33) 5 (33) 6 (33) 2 (25) 10 (34)
*No statistical significant correlations between Ep-CAM expression and the histopathological parameters were observed.BMC Cancer 2006, 6:165 http://www.biomedcentral.com/1471-2407/6/165
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done with SPSS and the statistical package R [28]. The
level of significance was set at p < 0.05.
Results
Expression of Ep-CAM in normal esophagus and 
esophageal SCC
In a first step, we investigated the Ep-CAM expression in
10 normal, non-pathologic squamous epithelia of the
esophagus. As previously reported [13], the non-patho-
logic esophageal squamous epithelium was negative for
Ep-CAM expression. In contrast four different levels of Ep-
CAM expression (Figure 1), which were classified accord-
ing to the Dako scoring system, were observed in the 70
esophageal SCC. We found 3+ Ep-CAM expression in 29/
70 of the investigated tumors (41%). Eight of the 70 sam-
ples were scored as 2+ (11%) and their membranous Ep-
CAM staining was less intense, when compared to the 3+
samples. A weak Ep-CAM staining scored as 1+ was
observed in 18/70 (26%) tumors and an absent expres-
sion of Ep-CAM was detected in 15/70 tumors (21%).
Neither in the complete patient collective (n = 70) nor in
the group with clinical follow up (n = 53, Table 1 and 2,
respectively) any statistical significant correlation between
the level of Ep-CAM expression and the clinico-patholog-
ical parameters pT-category, pN-category and grading
were observed. It is important to note that a heterogene-
ous Ep-CAM expression was seen at all expression levels
and no correlation was observed between Ep-CAM heter-
ogeneity within a tumor and its Ep-CAM expression score
(Chi-square test, p = 0.134). Also, a specific staining pat-
tern, e.g. intense staining at the invasive front, was not
detected.
Prognostic influence of Ep-CAM expression in esophageal 
SCC
In the 53 patients with follow-up data and a median
observation time of 15.0 months (range: 2 – 95 months)
we found, that the general neo-expression of Ep-CAM (1+
- 3+) did not correlate with the patient's prognosis. The
median cumulative disease-specific survival of the
patients was 17.0 months for Ep-CAM 1+ - 3+ positive
tumors and 24.0 months for Ep-CAM negative tumors
(log rank, p = 0.3491; relapse-free survival: Ep-CAM 1+ -
3+ 16.0 months vs. Ep-CAM negative 43.0 months; log
rank, p = 0.5993). Interestingly, tumors exhibiting a
strong Ep-CAM expression (3+) conferred a significantly
decreased median relapse-free survival interval. The
median cumulative relapse-free survival interval of
patients with Ep-CAM 3+ expression was 9.0 months,
compared to 43.0 months for patients with 0 - 2+ Ep-CAM
expression (log rank, p = 0.0001) (Figure 2A). The median
disease-specific survival was 11.0 months for patients
with Ep-CAM 3+ expressing tumors compared to > 24.0
months for those with 0-2+ Ep-CAM staining (log rank, p
= 0.0003, Figure 2B). As expected, the pN-category was
also of prognostic significance in our investigated series
with a median disease-specific survival of 13.0 months for
patients with positive nodal status compared to 75.0
months for patients without regional lymph node
involvement (log rank, p = 0.0170). The prognostic value
of the pT-category for disease-specific survival was not sta-
tistically significant (pT1–2 vs. pT 3–4, 16 months vs. 28
months, respectively; log rank, p = 0.1178). Tumor grad-
ing was also of no prognostic significance.
For multivariate regression analysis we included Ep-CAM
expression (Ep-CAM 3+ vs. Ep-CAM 0-2+), sex, age, pN,
pT and grading. We found an independent prognostic
influence for Ep-CAM 3+ on relapse-free survival and dis-
ease-specific survival (p = 0.002 and p = 0.005, respec-
tively) (Table 3). We also tested the possible interaction
between the pN category and Ep-CAM expression within
a multivariate model and confirmed the indepence of
both, Ep-CAM and pN-category as independent prognos-
tic factors (data not shown).
Discussion
Here we present the first comprehensive study of Ep-CAM
expression in primary esophageal SCC and its impact on
prognosis. In our study, almost 80% of the primary
esophageal SCC showed de novo expression of Ep-CAM
within the primary tumor, while normal squamous
mucosa was negative for Ep-CAM expression. To quantify
the level of Ep-CAM expression we used the evaluation cri-
teria for the FDA approved HercepTest (Dako) for quanti-
fication of the ERBB2  (HER2) gene product p185, the
target for the therapeutic antibody trastuzumab (Hercep-
tin). We used these guidelines because, comparable to
Table 3: Multivariate survival analysis for relapse-free and tumor-related survival of patients with esophageal SCC after best model 
selection by BIC.
Variable Relative risk of death (CI 95%) p-value
Relapse-free survival
Lymph node metastasis Present vs. absent 3.068 (1.434 – 5.950) < 0.001
Ep-CAM expression 3+ vs. 0 - 2+ 5.392 (1.831 – 15.878) < 0.001
Tumor-related survival
Lymph node metastasis Present vs. absent 2.924 (1.577 – 5.421) < 0.001
Ep-CAM expression 3+ vs. 0 - 2+ 3.762 (1.471 – 9.619) < 0.001BMC Cancer 2006, 6:165 http://www.biomedcentral.com/1471-2407/6/165
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p185, Ep-CAM is a membranous protein, and the criteria
are standardized and are already used to assign patients to
antibody-based therapy. The benefit or special applicabil-
ity of the Hercep-Test Scoring System to evaluate EpCAM
staining is so far unproven and needs to be confirmed in
independent future studies. However, applying this scor-
ing system, we identified three different levels of Ep-CAM
expression. Interestingly, strong (3+) Ep-CAM expression
was of prognostic significance. A correlation of strong Ep-
CAM expression and poor prognosis has been also
observed in breast cancer [15,16] and in gallbladder can-
cer [17]. In SCC of the lung, strong Ep-CAM expression
was positively correlated to lymph node metastasis and
larger tumors, however a correlation to survival could not
been demonstrated [29].
Several lines of evidence point to the importance of this
molecule in the early phase of squamous cell cancer pro-
gression. First, Ep-CAM de novo expression was already
noted in weak, mild and severe dysplasias of squamous
epithelium [14]. Second, this protein is expressed in the
early phase of tumor cell dissemination and metastasis in
esophageal and lung SCC, respectively. Ep-CAM expres-
sion is used to identify single tumor cells that have dis-
seminated to lymph nodes and are associated with a poor
prognosis [24,30,31]. Their malignant genotype was
recently disclosed by single cell comparative genomic
hybridization [32] and our group was able to demonstrate
the proliferative capacity and tumorigenicity of these cells
[33].
So far, the exact mechanisms of action of Ep-CAM contrib-
uting to the malignant potential of tumor cells are not
Ep-CAM expression in esophageal SCC Figure 1
Ep-CAM expression in esophageal SCC. A, esophageal SCC without Ep-CAM neo-expression. B, Detail of a tumor with 
2+ Ep-CAM expression. C, Tumor with heterogeneous 3+ Ep-CAM expression (white arrow: strong expression; black arrow: 
faint expression) and D, shows a representative sample with homogenous 3+ Ep-CAM expression.BMC Cancer 2006, 6:165 http://www.biomedcentral.com/1471-2407/6/165
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fully understood. However, recently in vivo experiments
gave the first proof of a direct link between Ep-CAM and
cell cycle control. Münz et al. were able to show that upon
Ep-CAM overexpression c-myc is rapidly upregulated [34].
Ep-CAM overexpression resulted in decreased growth fac-
tor requirement, enhanced metabolic activity and colony
formation capacity. Importantly, expression of Ep-CAM
anti-sense mRNA reversed these actions and led to a
strong decrease in proliferation and metabolism. How-
ever, it is necessary to note in this context that functions
and actions of Ep-CAM in cancer progression may differ in
different cancer types. Although Ep-CAM expression is
low in normal gastric mucosa and an increasing expres-
sion was observed in intestinal metaplasia, loss of Ep-
CAM expression is a strong prognostic factor for poor sur-
vival in gastric cancer [35]. In renal cancer, loss of Ep-CAM
expression was correlated with larger tumors and the pres-
ence of metastases. A positive Ep-CAM expression of the
renal tumor cells was an independent prognostic marker
for improved survival [36]. The biology behind these
observations can be explained by in vitro and in vivo exper-
iments demonstrating reduced motility, invasiveness and
metastatic capability of Ep-CAM transfected cells
[9,11,37]. These opposed findings in the different tumor
types suggest a complex role of the Ep-CAM molecule,
which functions might be regulated by the different pre-
dominant histogenetic molecular pathways.
Since in esophageal SCC Ep-CAM is overexpressed, its
expression is associated with poor prognosis and its onco-
genic potential in vitro render Ep-CAM an attractive mole-
cule for adjuvant targeted therapy in this cancer. As a
matter of fact, in patients with Dukes C colon cancer the
administration of edrecolomab, a monoclonal murine
IgG1 antibody directed against Ep-CAM, following the
surgical tumor resection significantly improved overall
survival by reducing the risk of tumor recurrence [38]. But
this murine antibody rapidly looses its efficiency in
humans due to neutralization by anti-edrecolomab anti-
bodies [39] and other multicenter studies did not find
beneficial effects on patients survival [40,41]. However,
meanwhile, a fully humanized anti-Ep-CAM antibody
(MT201) was developed and its efficacy of antigen
dependent cellular cytotoxicity is by two orders of magni-
tude higher than that of edrecolomab [39]. More recently,
Schlereth et al. reported about the very high antitumor
efficacy of a bispecific single-chain antibody directed
against Ep-CAM and CD3, which enables the efficient
redirection and activation of tumor-resident T-cells [42].
Although we are aware, that our results of Ep-CAM expres-
sion in 70 esophageal SCC are somewhat preliminary and
must be confirmed by a larger independent tumor collec-
tive, they are the first indication for a role of Ep-CAM in
esophageal SCC progression. Neo-expression of Ep-CAM
is a frequent event in this cancer and strong expression
defines a subgroup with high risk for tumor relapse after
complete tumor removal. Thus, Ep-CAM testing and
application of therapeutic anti-EpCAM antibodies to suit-
able candidates represents a chance to improve the prog-
Prognostic impact of Ep-CAM Figure 2
Prognostic impact of Ep-CAM. Kaplan-Meier curves for relapse-free (A) and overall survival (B) calculated from 53 patients 
with esophageal SCC.BMC Cancer 2006, 6:165 http://www.biomedcentral.com/1471-2407/6/165
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nosis of esophageal SCC patients. This is particularly
suggested in the adjuvant situation, since the population
of minimal residual tumor cells is considered to be more
amenable to antibody-based therapies, compared to large
tumour masses in advanced stages of cancer [43].
Conclusion
In conclusion, our results suggest Ep-CAM as an attractive
molecule for targeted therapy in esophageal SCC, espe-
cially in the adjuvant situation. Considering the discon-
tenting results of the current adjuvant concepts for
esophageal SCC patients, anti-body based therapy
directed against Ep-CAM holds promise for more effective
eradication of minimal residual cancer to suppress lethal
metastatic disease.
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